News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily EnvarsusĀ® In Liver Transplant Patients


4/28/2014 8:59:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study demonstrating conversion from twice-daily tacrolimus to once-daily EnvarsusĀ® in stable liver transplant patients in Liver Transplantation.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES